BACKGROUND AND PURPOSE: Small-molecule glucokinase activators (GKAs) are currently being investigated as therapeutic options for the treatment of type 2 diabetes (T2D). Because liver overexpression of glucokinase is thought to be associated with altered lipid profiles, this study aimed at assessing the potential lipogenic risks linked to oral GKA administration. EXPERIMENTAL APPROACH: Nine GKA candidates were qualified for their ability to activate recombinant glucokinase and to stimulate glycogen synthesis in rat hepatocytes and insulin secretion in rat INS-1E cells. In vivo activity was monitored by plasma glucose and HbA1c measurements after oral administration in rodents. Risk-associated effects were assessed by measuring hepatic and plasma triglycerides and free fatty acids, as well as plasma aminotransferases, and alkaline phosphatase. KEY RESULTS: GKAs, while efficiently decreasing glycaemia in acute conditions and HbA1c levels after chronic administration in hyperglycemic db/db mice, were potent inducers of hepatic steatosis. This adverse outcome appeared as soon as 4 days after daily oral administration at pharmacological doses and was not transient. GKA treatment similarly increased hepatic triglycerides in diabetic and normoglycaemic rats, together with a pattern of metabolic phenotypes including different combinations of increased plasma triglycerides, free fatty acids, alanine and aspartyl aminotransferases, and alkaline phosphatase. GKAs belonging to three distinct structural families induced hepatic steatosis in db/db mice, arguing in favour of a target-mediated, rather than a chemical class-mediated, effect. CONCLUSION AND IMPLICATIONS: Given the risks associated with fatty liver disease in the general population and furthermore in patients with T2D, these findings represent a serious warning for the use of GKAs in humans. LINKED ARTICLE: This article is commented on by Rees and Gloyn, pp. 335-338 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476-5381.2012.02201.x.
BACKGROUND AND PURPOSE: Small-molecule glucokinase activators (GKAs) are currently being investigated as therapeutic options for the treatment of type 2 diabetes (T2D). Because liver overexpression of glucokinase is thought to be associated with altered lipid profiles, this study aimed at assessing the potential lipogenic risks linked to oral GKA administration. EXPERIMENTAL APPROACH: Nine GKA candidates were qualified for their ability to activate recombinant glucokinase and to stimulate glycogen synthesis in rat hepatocytes and insulin secretion in rat INS-1E cells. In vivo activity was monitored by plasma glucose and HbA1c measurements after oral administration in rodents. Risk-associated effects were assessed by measuring hepatic and plasma triglycerides and free fatty acids, as well as plasma aminotransferases, and alkaline phosphatase. KEY RESULTS: GKAs, while efficiently decreasing glycaemia in acute conditions and HbA1c levels after chronic administration in hyperglycemic db/db mice, were potent inducers of hepatic steatosis. This adverse outcome appeared as soon as 4 days after daily oral administration at pharmacological doses and was not transient. GKA treatment similarly increased hepatic triglycerides in diabetic and normoglycaemic rats, together with a pattern of metabolic phenotypes including different combinations of increased plasma triglycerides, free fatty acids, alanine and aspartyl aminotransferases, and alkaline phosphatase. GKAs belonging to three distinct structural families induced hepatic steatosis in db/db mice, arguing in favour of a target-mediated, rather than a chemical class-mediated, effect. CONCLUSION AND IMPLICATIONS: Given the risks associated with fatty liver disease in the general population and furthermore in patients with T2D, these findings represent a serious warning for the use of GKAs in humans. LINKED ARTICLE: This article is commented on by Rees and Gloyn, pp. 335-338 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476-5381.2012.02201.x.
Authors: M Futamura; J Yao; X Li; R Bergeron; J-L Tran; E Zycband; J Woods; Y Zhu; Q Shao; H Maruki-Uchida; H Goto-Shimazaki; R B Langdon; M D Erion; J Eiki; Y-P Zhou Journal: Diabetologia Date: 2012-01-11 Impact factor: 10.122
Authors: Katy J Brocklehurst; Victoria A Payne; Rick A Davies; Debra Carroll; Helen L Vertigan; Heather J Wightman; Susan Aiston; Ian D Waddell; Brendan Leighton; Matthew P Coghlan; Loranne Agius Journal: Diabetes Date: 2004-03 Impact factor: 9.461
Authors: Gary E Meininger; Russell Scott; Maria Alba; Yue Shentu; Edmund Luo; Himal Amin; Michael J Davies; Keith D Kaufman; Barry J Goldstein Journal: Diabetes Care Date: 2011-10-12 Impact factor: 19.112
Authors: D J Baker; G P Wilkinson; A M Atkinson; H B Jones; M Coghlan; A D Charles; B Leighton Journal: Br J Pharmacol Date: 2014-04 Impact factor: 8.739
Authors: L Maria Belalcazar; George D Papandonatos; Bahar Erar; Inga Peter; Hadeel Alkofide; Ashok Balasubramanyam; Ariel Brautbar; Steven E Kahn; William C Knowler; Christie M Ballantyne; Jeanne M McCaffery; Gordon S Huggins Journal: Circ Cardiovasc Genet Date: 2015-11-17
Authors: Jose Cordoba-Chacon; Neena Majumdar; Edward O List; Alberto Diaz-Ruiz; Stuart J Frank; Anna Manzano; Ramon Bartrons; Michelle Puchowicz; John J Kopchick; Rhonda D Kineman Journal: Diabetes Date: 2015-05-26 Impact factor: 9.461
Authors: Benjamin G Challis; Julie Harris; Alison Sleigh; Iona Isaac; Steve M Orme; Nandini Seevaratnam; Ketan Dhatariya; Helen L Simpson; Robert K Semple Journal: Clin Endocrinol (Oxf) Date: 2014-07-02 Impact factor: 3.478
Authors: Abudukadier Abulizi; Rebecca L Cardone; Romana Stark; Sophie L Lewandowski; Xiaojian Zhao; Joelle Hillion; Lingjun Ma; Raghav Sehgal; Tiago C Alves; Craig Thomas; Charles Kung; Bei Wang; Stephan Siebel; Zane B Andrews; Graeme F Mason; Jesse Rinehart; Matthew J Merrins; Richard G Kibbey Journal: Cell Metab Date: 2020-11-03 Impact factor: 27.287